EICHORCondition: Hypopigmentation · Sponsor: Centre Hospitalier Universitaire de Nice
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Hypopigmented skin changes are commonly encountered by dermatologists. A new dermatological entity was identified as scattered, hypopigmented oval-shaped macules and patches distributed mostly in seborrheic area of the face and of the trunk in dark skinned individuals. This patterned presentation of hypopigmentation was first described in the literature under the name of hypochromic vitiligo or vitiligo minor. Nerveless, histopathological patient's specimens analyzed by Krueger et al. clearly highlight that there is no tangible causal correlation with a diagnosis of vitiligo. They propose to rename this entity to Seborrheic Macular Hypopigmentation (SMH). The etiopathology of this dermatosis is still unknown preventing to propose any satisfactory treatment for this disfiguring affection.The objective of this study is to analyze the bacterial and fungal skin microbiome on hypochromic lesions of SMH compared to the surrounding non-lesional skin of the same patients and to healthy volunteers
This description comes directly from the study's public registry record.
Thierry Passeron, PhD · +33492036488 · passeron.t@chu-nice.fr
emmanuelle PRADELLI · +33492036488 · pradelli.e@chu-nice.fr
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Female and male patients ≥ 18 years of age 2. Clinical diagnosis of SMH with lesion of the face 3. Written informed consent obtained before any assessment is performed 4. Affiliation with a social security scheme 5. Physical and psychological ability to participate Exclusion Criteria: 1. Use of systemic antibiotics or any systemic antifungal treatments within 4 weeks before the inclusion visit 2. Use of topical antibiotics or any topical antifungal treatments on the face within 2 weeks before the inclusion visit 3. Use of any topical cream, gel, serum or ointment within 2 days before the inclusion visit 4. Laser, radiofrequency, peeling or any other procedure on the face in the past 3 months before the inclusion visit 5. Vulnerable patients: minors, patients under guardianship or curatorship, pregnant or breast-feeding women
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| CHU de Nice - Hôpital de l'Archet | Nice, Alpes-Maritimes, France | Recruiting |
| Hôpital Louis Pasteur, hôpitaux Civils de Colmar | Colmar, Colmar, France | Recruiting |
| Hôpital Saint-Louis - APHP | Paris, Île-de-France Region, France | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06908889